Cart:

Let food be thy medicine and medicine be thy food.

But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system.

Discover the Benefitst of GLP1 Tirzepatide 30mg

Shop now

GLP-1 Peptides and Tirzepatide: A Short History and Philippine

A Quick History

Incretins & GLP-1 (1980s–2000s)

Researchers mapping the proglucagon gene identified glucagon-like peptide-1 (GLP-1).
GLP-1 was shown to enhance meal-time insulin secretion and reduce glucagon—this “incretin effect” became the basis for GLP-1 receptor agonist (GLP-1 RA) drugs.

First GLP-1 Medicine (2005)

Exenatide (Byetta) became the first GLP-1 RA approved for type 2 diabetes, validating the approach in humans.

GLP-1 for Obesity (2014–2021)

Liraglutide 3 mg (Saxenda) was approved in 2014 as the first GLP-1 specifically for chronic weight management.
Higher-dose semaglutide 2.4 mg (Wegovy) followed in 2021 after trials showed large average weight loss when paired with lifestyle changes.

The “Twincretin” Tirzepatide (2022–2023)

Tirzepatide activates both GIP and GLP-1 receptors.
Approved in 2022 for type 2 diabetes (brand: Mounjaro) and in 2023 for chronic weight management (brand: Zepbound).

How Research Turned Into Human Use for Weight Loss

Mechanisms suggested weight effects:
GLP-1 (and GIP/GLP-1) slow gastric emptying, reduce appetite, and improve post-meal insulin responses.
Diabetes trials noticed weight loss:
Early studies in type 2 diabetes consistently showed weight reductions, which led to dedicated obesity trials
(e.g., SCALE with liraglutide, STEP with semaglutide, SURMOUNT with tirzepatide).
Broader evidence accumulated:
Real-world data and meta-analyses show clinically meaningful weight loss, with tirzepatide often producing the largest averages among marketed agents.

What This Looks Like in the Philippines

Locally available indications:
- Ozempic (semaglutide): indicated for type 2 diabetes.
- Saxenda (liraglutide 3 mg): approved for chronic weight management in eligible patients.
- Wegovy (semaglutide 2.4 mg): international approval for obesity; local availability and timing have been evolving.
- Tirzepatide (Mounjaro/Zepbound): global approvals include diabetes (Mounjaro) and weight management (Zepbound); check Philippine FDA registration and indications for current local status.
Access and verification: Obtain these medicines via licensed physicians and FDA-registered pharmacies.
Use the Philippine FDA’s product verification tools to confirm brand, strength, and indication.
Safety notes: Health authorities caution against off-label or social-media-driven use and against non-approved or compounded sources.

Fast Timeline (Global → PH)

1986–1990s: GLP-1 identified; incretin effects characterized in humans.
2005: Exenatide approved for diabetes.
2014: Liraglutide 3 mg (Saxenda) approved for chronic weight management.
2021: Semaglutide 2.4 mg (Wegovy) approved for obesity after STEP trials.
2022: Tirzepatide (Mounjaro) approved for type 2 diabetes.
2023: Tirzepatide (Zepbound) approved for chronic weight management.
Philippines (ongoing): Saxenda carries a weight-management indication; Ozempic is diabetes-only; other products’ local availability and indications should be checked with the PH FDA and specialty society guidance.

Bottom Line

GLP-1–based medicines and tirzepatide emerged from decades of incretin research. After diabetes trials revealed consistent weight effects, dedicated obesity studies led to formal weight-management approvals. In the Philippines, legitimate access runs through physicians and FDA-registered pharmacies, with indications varying by brand and dose. Always verify local registration and use medical supervision for safe, effective treatment.

Our responsibility

As a collective, Biona community works together to advance the science of food and one another through the following shared values:

Community